Researchers Submit Patent Application, "Cereblon Ligands and Uses Thereof", for Approval (USPTO 20240059711).

A patent application titled "Cereblon Ligands and Uses Thereof" has been submitted by a group of inventors. The application discusses the role of cereblon (CRBN) in the degradation of target proteins and its connection to immunomodulatory agents like thalidomide and lenalidomide. The inventors propose compounds and conjugates that can bind to the cereblon E3 ubiquitin ligase protein complex, potentially leading to the degradation of specific proteins. The application also mentions the development of PROTACs molecules based on CRBN ligands. This information may be useful for researchers studying protein degradation and the treatment of diseases. [Extracted from the article]